PATENT 512585-2001 JC03 Rec'd PCI/i TO 1 7 AUG 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

TAGG, et al.

U.S. Serial No.

To be assigned

Filing Date

Herewith

Title of Invention

LANTIBIOTIC

745 Fifth Avenue New York, NY 10151

EXPRESS MAIL

Mailing Label Number:

EL819168818US

Date of Deposit:

August 17, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, DC 20231.

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed are copies of the following references for this application:

- 1. U.S. Patent No. 3,925,160, dated December 9, 1975;
- Kalmokoff, et al., "Evidence for Production of a New Lantibiotic
 (Butyrivibriocin OR79A) by the Ruminal Anaerobe *Butyrivibrio fibrisolvens* OR79: Characterization of the Structural Gene Encoding

Butyrivibriocin OR79A", Applied and Environmental Microbiology, Vol. 65, No. 5, May 1999, pp. 2128-2135; and

3. Ross, et al., "Isolation and Characterization of the Lantibiotic Salivaricin A and Its Structural Gene salA from Streptococcus salivarius 20P3", Applied and Environmental Microbiology, Vol. 59, No. 7, July 1993, pp. 2014-2021.

REMARKS

Entry of this Information Disclosure Statement and an early examination on the merits are respectfully solicited.

Please charge any additional fees to Deposit Account No. 50-0320.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP Attorneys for Applicants

Зу__

William F. Lawrence

Reg. No. 28,029

Tel. (212) 588-0800

WFL/ds

Encs.